Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Laurence P. Diggs, Eddy C. Hsueh
Biomarker Research (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 165

Showing 1-25 of 165 citing articles:

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye, Zoaib Rasool
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 619
The emerging clinical relevance of genomics in cancer medicine
Michael F. Berger, Elaine R. Mardis
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 6, pp. 353-365
Open Access | Times Cited: 503
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu, Xu Wang, Lei Wang, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 349
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson, Karen J. Scott, David Taggart, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 422
Open Access | Times Cited: 335
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li, Changshun Shao, Yufang Shi, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 321
Immuno-Oncology: Emerging Targets and Combination Therapies
Henry T. Marshall, Mustafa B.A. Djamgoz
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 280
Current Development Status of MEK Inhibitors
Ying Cheng, Hongqi Tian
Molecules (2017) Vol. 22, Iss. 10, pp. 1551-1551
Open Access | Times Cited: 241
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Yoshiyuki Nakamura
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 172
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora, R. A. Velichinskii, Randy W. Lesh, et al.
Advances in Therapy (2019) Vol. 36, Iss. 10, pp. 2638-2678
Open Access | Times Cited: 172
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Xinyao Qiu, Shuai Yang, Shan Wang, et al.
Cancer Research (2021) Vol. 81, Iss. 18, pp. 4778-4793
Open Access | Times Cited: 167
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
Emeric Limagne, Corentin Richard, Marion Thibaudin, et al.
OncoImmunology (2019) Vol. 8, Iss. 4, pp. e1564505-e1564505
Open Access | Times Cited: 155
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma
Paul Johannet, Nicolas Coudray, Douglas M. Donnelly, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 1, pp. 131-140
Open Access | Times Cited: 142
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
Diana Merino Vega, Laura M. Yee, Lisa M. McShane, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1626-1636
Open Access | Times Cited: 132
The Emerging Role of Raman Spectroscopy as an Omics Approach for Metabolic Profiling and Biomarker Detection toward Precision Medicine
Gabriel Cutshaw, Saji Uthaman, Nora Hassan, et al.
Chemical Reviews (2023) Vol. 123, Iss. 13, pp. 8297-8346
Open Access | Times Cited: 72
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features
Tiangen Chang, Yingying Cao, Hannah J. Sfreddo, et al.
Nature Cancer (2024) Vol. 5, Iss. 8, pp. 1158-1175
Open Access | Times Cited: 29
FLT3 inhibitors in acute myeloid leukemia
Mei‐Hwan Wu, Chuntuan Li, Xiongpeng Zhu
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 144
Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi‐Long Wu, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 143
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Aung Naing, Funda Meric‐Bernstam, Bettzy Stephen, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000347-e000347
Open Access | Times Cited: 117
89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer
Christopher G. England, Dawei Jiang, Emily B. Ehlerding, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2017) Vol. 45, Iss. 1, pp. 110-120
Open Access | Times Cited: 114
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Bingshan Liu, Yongping Song, Delong Liu
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 107
Emerging therapies in advanced hepatocellular carcinoma
Sowmini Medavaram, Yue Zhang
Experimental Hematology and Oncology (2018) Vol. 7, Iss. 1
Open Access | Times Cited: 107
Cancer biomarkers for targeted therapy
Delong Liu
Biomarker Research (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 97
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long, Jianzhen Lin, Anqiang Wang, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 96
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result
Mengmeng Jiang, Dazhen Sun, Yinglong Guo, et al.
Academic Radiology (2019) Vol. 27, Iss. 2, pp. 171-179
Closed Access | Times Cited: 95
Emerging agents and regimens for hepatocellular carcinoma
Xiao‐Dong Zhu, Hui‐Chuan Sun
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 93
Page 1 - Next Page

Scroll to top